Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 688 results
Found 688 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

H

Hennig S, Naiker S, Reddy T, et al. "Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis." Antimicrob. Agents Chemother.. 2015;60(1):617-20.
Hennig S, Svensson EM, Niebecker R, et al. "Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs." J. Antimicrob. Chemother.. 2016;71(5):1330-40.
Henrich TJ, Ribaudo HJ, Kuritzkes DR. "Instantaneous inhibitory potential is similar to inhibitory quotient at predicting HIV-1 response to antiretroviral therapy." Clin. Infect. Dis.. 2010;51(1):93-8.
Henrich TJ, Hanhauser E, Harrison LJ, et al. "CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy." J. Infect. Dis.. 2016;213(5):766-70.
Henrich TJ, McLaren PJ, Rao SSP, et al. "Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study." Open Forum Infect Dis. 2014;1(1):ofu018.
Henrich TJ, Lewine NRP, Lee S-H, et al. "Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists." Antimicrob. Agents Chemother.. 2012;56(4):1931-5.
Henrich TJ, Tsibris AMN, Lewine NRP, et al. "Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate." J. Acquir. Immune Defic. Syndr.. 2010;55(4):420-7.
Henry K, Katzenstein D, Cherng DWeng, et al. "A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102." J. Acquir. Immune Defic. Syndr.. 2006;42(2):140-8.
Hermes A, Squires K, Fredrick L, et al. "Meta-analysis of the safety, tolerability, and efficacy of lopinavir/ritonavir-containing antiretroviral therapy in HIV-1-infected women." HIV Clin Trials. 2012;13(6):308-23.
Hitti J, Halvas EK, Zheng L, et al. "Frequency of Antiretroviral Resistance Mutations among Infants Exposed to Single-Dose Nevirapine and Short Course Maternal Antiretroviral Regimens: ACTG A5207." J AIDS Clin Res. 2014;5(11).
Hitti J, Andersen J, McComsey G, et al. "Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084." Am. J. Obstet. Gynecol.. 2007;196(4):331.e1-7.
Hochreiter J, Lapham J, Wong-Staal F, et al. "ITX 5061 quantitation in human plasma with reverse phase liquid chromatography and mass spectrometry detection." Antivir. Ther. (Lond.). 2013;18(3):329-36.
Hoffman RM, Jamieson BD, Bosch RJ, et al. "Baseline immune phenotypes and CD4+ T lymphocyte responses to antiretroviral therapy in younger versus older HIV-infected individuals." J. Clin. Immunol.. 2011;31(5):873-81.
Hogan CM, Degruttola V, Sun X, et al. "The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals." J. Infect. Dis.. 2012;205(1):87-96.
Holzinger ER, Grady B, Ritchie MD, et al. "Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants." Pharmacogenet. Genomics. 2012;22(12):858-67.
Hosoya N, Su Z, Wilkin T, et al. "Assessing human immunodeficiency virus type 1 tropism: Comparison of assays using replication-competent virus versus plasma-derived pseudotyped virions." J. Clin. Microbiol.. 2009;47(8):2604-6.
Hosseinipour MC, Bisson GP, Miyahara S, et al. "Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial." Lancet. 2016;387(10024):1198-209.
Hosseinipour MC, Kang M, Krown SE, et al. "As-Needed versus Immediate Etoposide Chemotherapy in Combination with Antiretroviral Therapy for Mild or Moderate AIDS-associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial." Clin. Infect. Dis.. 2018.
Hu Z, Kuritzkes DR. "Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1." J. Virol.. 2011;85(21):11309-14.
Hu Z, Hatano H, Hammond SP, et al. "Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptase." J. Acquir. Immune Defic. Syndr.. 2007;45(5):494-500.
X Hu J, Lagakos SW. "Nonparametric estimation of the mean function of a stochastic process with missing observations." Lifetime Data Anal. 2007;13(1):51-73.
Hu Z, Kuritzkes DR. "Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness." J. Acquir. Immune Defic. Syndr.. 2010;55(2):148-55.
Hua L, Andersen JW, Daar ES, Glesby MJ, Hollabaugh K, Tierney C. "Hepatitis C virus/HIV coinfection and responses to initial antiretroviral treatment." AIDS. 2013;27(17):2725-34.
Huang Y, Liu D, Wu H. "Hierarchical Bayesian methods for estimation of parameters in a longitudinal HIV dynamic system." Biometrics. 2006;62(2):413-23.
Huang JS, Hughes MD, Riddler SA, Haubrich RH. "Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142." HIV Clin Trials. 2013;14(5):224-34.
Huang X-L, Fan Z, Borowski L, Rinaldo CR. "Maturation of dendritic cells for enhanced activation of anti-HIV-1 CD8(+) T cell immunity." J. Leukoc. Biol.. 2008;83(6):1530-40.
Hubbard JJ, Greenwell-Wild T, Barrett L, et al. "Host gene expression changes correlating with anti-HIV-1 effects in human subjects after treatment with peginterferon Alfa-2a." J. Infect. Dis.. 2012;205(9):1443-7.
Hughes MD, Williams PL. "Challenges in using observational studies to evaluate adverse effects of treatment." N. Engl. J. Med.. 2007;356(17):1705-7.
Hulgan T, Donahue JP, Smeaton L, et al. "Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitors." Eur. J. Clin. Pharmacol.. 2009;65(11):1081-8.
Hulgan T, Hughes M, Sun X, et al. "Oxidant stress and peripheral neuropathy during antiretroviral therapy: an AIDS clinical trials group study." J. Acquir. Immune Defic. Syndr.. 2006;42(4):450-4.

Pages